

abbvie

PATIENT CARD

Keep this card with you
(or caregiver) all the time

Safety Information about **RINVOQ**[®] (upadacitinib) for Patients



This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effect you may get to Fimea: www.fimea.fi or to the local representative of the marketing authorisation holder (AbbVie Oy).

This card contains important safety information you should be aware of – before and during treatment with **RINVOQ**.

Risk of infections

RINVOQ may make an existing infection worse or increase the chance of you getting a new infection – for example tuberculosis (TB), shingles or viral hepatitis.

Tell your doctor straight away if you notice signs of infection, such as:

- Fever, sweating, chills, weight loss, or a cough that won't go away – these may be signs of TB.
- Painful skin rash with blisters – this may be a sign of shingles.
- Feeling tired or short of breath – this may be a sign of pneumonia.

Vaccines – used to help prevent infections

Live vaccines (for example influenza vaccine by nasal spray, varicella, measles/mumps/rubella) should not be given during RINVOQ treatment, or just before starting RINVOQ treatment.

Before being given any vaccines, talk to your doctor – they will know which vaccines you should **not** be given before or during treatment with RINVOQ.

Risk of heart disease

Treatment with RINVOQ was associated with increases in cholesterol (blood fat). Your doctor will check your cholesterol levels while you are taking RINVOQ.

Tell your doctor straight away if you notice symptoms such as chest pain or tightness since this may be a symptom of heart disease.

Risk of blood clots in veins or lungs

Blood clots in veins or lungs have been observed with RINVOQ. Tell your doctor straight away if you get signs of blood clots in veins or lungs, such as a painful swollen leg, shortness of breath, or chest pain.

Contraception, pregnancy, and breast-feeding

RINVOQ must not be taken during pregnancy.

- Use effective contraception while taking RINVOQ – and for 4 weeks after your last dose. Talk to your doctor about effective contraception.
- Tell your doctor straight away if you wish to become pregnant, or if you become pregnant.
- Do not breast-feed while using RINVOQ.

Risk of cancers

RINVOQ may potentially increase your risk of developing cancers particularly skin cancer.

Let your doctor know if you notice any change in the appearance of an area on your skin, or notice any new growth on your skin.

Risk of a hole in your bowel

RINVOQ may increase your risk of a hole in your bowel especially if you have Crohn's disease. Tell your doctor straight away if you have unexplained or unexpected stomach pain.

Show this card to any
healthcare professional involved
in your medical care –
for example, your dentist or
an emergency doctor.

Read the patient information leaflet
for more information or
scan the QR-code below.



www.fimea.fi

Finnish Medicines Agency Fimea
Register for adverse drug reactions
P.O. Box 55, FI-00034 FIMEA

Your name:

Name of physician who
prescribed **RINVOQ**:

Physician's phone number:

The date you started **RINVOQ**:

Version 4.0. February 2023.

FI-RNQ-210029/RMP/14.8.2023

AbbVie Oy
Tel. 010 2411 200